MX2016015695A - Metodos para tratar y prevenir enfermedades de inestabilidad vascular. - Google Patents
Metodos para tratar y prevenir enfermedades de inestabilidad vascular.Info
- Publication number
- MX2016015695A MX2016015695A MX2016015695A MX2016015695A MX2016015695A MX 2016015695 A MX2016015695 A MX 2016015695A MX 2016015695 A MX2016015695 A MX 2016015695A MX 2016015695 A MX2016015695 A MX 2016015695A MX 2016015695 A MX2016015695 A MX 2016015695A
- Authority
- MX
- Mexico
- Prior art keywords
- ccm
- methods
- disclosed
- patient
- lesion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- High Energy & Nuclear Physics (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos para tratar y prevenir enfermedades de inestabilidad vasculares, tales como malformación cavernosa cerebral, por la administración de tempol, colecalciferol, derivados de los mismos, sales farmacéuticamente aceptables de los mismos, o combinaciones de los mismos. Se describen métodos para reducir el número de lesiones de malformación cavernosa cerebral (CCM) en un paciente que tiene, o en riesgo de desarrollar, por lo menos una lesión de CCM. Se describen métodos para la reducción de la tasa de crecimiento del número de lesiones de malformación cavernosa cerebral (CCM) en un paciente que tiene, o en riesgo de desarrollar, por lo menos una lesión de CCM. El método se describe para prevenir o tratar un signo o síntoma de la malformación cavernosa cerebral (CCM) en un paciente con por lo menos una lesión de CCM. Se describen métodos para disminuir la inflamación cerebrovascular, reduciendo la permeabilidad cerebrovascular, o ambos, en un paciente que tiene, o en riesgo de desarrollar, una lesión de malformación cavernosa cerebral (CCM). Se describen métodos para mejorar la salud vascular cerebral en un paciente que tiene, o en riesgo de lesión en desarrollar, una malformación cavernosa cerebral (CCM).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462014540P | 2014-06-19 | 2014-06-19 | |
US14/728,800 US9314457B2 (en) | 2014-06-19 | 2015-06-02 | Methods of treating and preventing vascular instability diseases |
PCT/US2015/036062 WO2015195685A1 (en) | 2014-06-19 | 2015-06-16 | Methods of treating and preventing vascular instability diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016015695A true MX2016015695A (es) | 2017-05-30 |
Family
ID=54868659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016015695A MX2016015695A (es) | 2014-06-19 | 2015-06-16 | Metodos para tratar y prevenir enfermedades de inestabilidad vascular. |
Country Status (14)
Country | Link |
---|---|
US (2) | US9314457B2 (es) |
EP (1) | EP3157532B1 (es) |
JP (1) | JP6621424B2 (es) |
KR (1) | KR102419504B1 (es) |
CN (1) | CN106659727B (es) |
AU (1) | AU2015277341B2 (es) |
BR (1) | BR112016029437B1 (es) |
CA (1) | CA2949545C (es) |
DK (1) | DK3157532T3 (es) |
ES (1) | ES2879331T3 (es) |
IL (1) | IL249599B (es) |
MX (1) | MX2016015695A (es) |
RU (1) | RU2712170C2 (es) |
WO (1) | WO2015195685A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314457B2 (en) * | 2014-06-19 | 2016-04-19 | The University Of Utah Research Foundation | Methods of treating and preventing vascular instability diseases |
US20190111111A1 (en) * | 2016-04-13 | 2019-04-18 | The Regents Of The University Of California | Treatment of Cerebral Cavernous Malformations |
CN106226531B (zh) * | 2016-07-25 | 2018-05-22 | 广州道瑞医药科技有限公司 | Angpt2在筛选或制备用于诊断或治疗血管瘤的药物中的应用 |
US20210128527A1 (en) * | 2017-12-08 | 2021-05-06 | Graham Timmins | Compositions and methods for treating hemorrhagic stroke |
US20220378765A1 (en) * | 2021-05-25 | 2022-12-01 | Louis Habash | Adjusting expression level of a gene encoding a sirtuin protein by treating a human subject with a nitroxide |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096759A (en) | 1997-09-19 | 2000-08-01 | Georgetown University | Method for treating essential hypertension |
JP4590523B2 (ja) | 1997-11-25 | 2010-12-01 | アンティポディーン ファーマシューティカルズ インコーポレイテッド | ミトコンドリアを標的とする抗酸化剤 |
US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
AU2001293064A1 (en) | 2000-09-26 | 2002-04-08 | Georgetown University | Use of nitroxides for the treatment of vascular disorders in a diabetic mammal |
NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
CN100469776C (zh) | 2002-05-17 | 2009-03-18 | 奥特拉控股公司 | 白内障和其它眼病发展的改善 |
AU2005208821B8 (en) | 2003-02-04 | 2010-10-14 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
CA2523565A1 (en) * | 2003-04-25 | 2004-11-11 | Mitos Incorporated | Prophylactic pretreatment with antioxidants |
BRPI0413742B8 (pt) | 2003-08-22 | 2021-05-25 | Antipodean Pharmaceuticals Inc | composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante |
EP1691818A4 (en) | 2003-11-25 | 2007-01-24 | Univ Rochester | COMPOUNDS FOR DELIVERING AMINO ACIDS OR PEPTIDES WITH ANTIOXIDANT ACTIVITY IN MITOCHONDRIES AND USE THEREOF |
RU2264241C2 (ru) * | 2004-02-05 | 2005-11-20 | Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова | Способ лечения поражений зрительного анализатора |
US20070167419A1 (en) * | 2005-03-02 | 2007-07-19 | The Regents Of The University Of California | Treatment for embolic stroke |
WO2006113531A2 (en) | 2005-04-14 | 2006-10-26 | Cary Pharmaceuticals | Combination formulation |
US7691896B2 (en) | 2005-08-10 | 2010-04-06 | President And Fellows Of Harvard College | Analogs of salinosporamide A |
EP1954685A4 (en) | 2005-11-16 | 2009-11-11 | Nitromed Inc | FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
US7910607B2 (en) * | 2006-03-10 | 2011-03-22 | The Trustees Of California State University | Nitroxide free radical synergized antineoplastic agents |
US20070275944A1 (en) | 2006-04-05 | 2007-11-29 | The Board Of Trustees Operating Michigan State University | Antioxidants and methods of their use |
US7754463B2 (en) | 2006-06-20 | 2010-07-13 | Dana-Farber Cancer Institute | Inhibitors of USP1 Deubiquitinating Enzyme Complex |
US7923037B2 (en) | 2006-10-05 | 2011-04-12 | Ikaria, Inc. | Liquid chalcogenide compositions and methods of manufacturing and using the same |
EP2120942A2 (en) | 2007-02-16 | 2009-11-25 | Othera Holding, Inc. | Drug resistance reversal in neoplastic disease |
US8466130B2 (en) * | 2009-09-04 | 2013-06-18 | Colby Pharmaceutical Company | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers |
NZ587105A (en) | 2008-01-22 | 2012-09-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
US20100081689A1 (en) | 2008-09-26 | 2010-04-01 | Georgetown University | Methods and Compositions for the Treatment of Iron Toxicity |
US20110130421A1 (en) | 2009-10-29 | 2011-06-02 | Georgetown University | Methods and Compositions for the Treatment of Chronic Renal Hypertension |
US8853277B2 (en) | 2009-11-30 | 2014-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC) |
RU2476249C2 (ru) * | 2011-06-02 | 2013-02-27 | Федеральное государственное учреждение "Центральный научно-исследовательский институт стоматологии и челюстно-лицевой хирургии" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения сосудистых мальформаций |
KR20130016127A (ko) | 2011-08-04 | 2013-02-14 | 의료법인 성광의료재단 | 외상성 뇌손상의 치료 |
US9314457B2 (en) * | 2014-06-19 | 2016-04-19 | The University Of Utah Research Foundation | Methods of treating and preventing vascular instability diseases |
-
2015
- 2015-06-02 US US14/728,800 patent/US9314457B2/en active Active
- 2015-06-16 BR BR112016029437-8A patent/BR112016029437B1/pt active IP Right Grant
- 2015-06-16 KR KR1020167035376A patent/KR102419504B1/ko active IP Right Grant
- 2015-06-16 DK DK15809709.7T patent/DK3157532T3/da active
- 2015-06-16 ES ES15809709T patent/ES2879331T3/es active Active
- 2015-06-16 MX MX2016015695A patent/MX2016015695A/es unknown
- 2015-06-16 WO PCT/US2015/036062 patent/WO2015195685A1/en active Application Filing
- 2015-06-16 EP EP15809709.7A patent/EP3157532B1/en active Active
- 2015-06-16 CN CN201580031241.5A patent/CN106659727B/zh active Active
- 2015-06-16 RU RU2016145265A patent/RU2712170C2/ru active
- 2015-06-16 AU AU2015277341A patent/AU2015277341B2/en active Active
- 2015-06-16 JP JP2016573868A patent/JP6621424B2/ja active Active
- 2015-06-16 CA CA2949545A patent/CA2949545C/en active Active
-
2016
- 2016-04-08 US US15/094,561 patent/US9937162B2/en active Active
- 2016-12-15 IL IL249599A patent/IL249599B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2015277341B2 (en) | 2020-06-25 |
EP3157532A1 (en) | 2017-04-26 |
AU2015277341A1 (en) | 2016-12-01 |
IL249599B (en) | 2021-06-30 |
CN106659727A (zh) | 2017-05-10 |
DK3157532T3 (da) | 2021-06-28 |
BR112016029437A2 (pt) | 2017-08-22 |
KR20170021249A (ko) | 2017-02-27 |
EP3157532B1 (en) | 2021-03-24 |
CA2949545C (en) | 2022-07-19 |
RU2016145265A3 (es) | 2019-02-04 |
EP3157532A4 (en) | 2017-12-20 |
US9314457B2 (en) | 2016-04-19 |
IL249599A0 (en) | 2017-02-28 |
JP2017518340A (ja) | 2017-07-06 |
US20160220546A1 (en) | 2016-08-04 |
US9937162B2 (en) | 2018-04-10 |
RU2712170C2 (ru) | 2020-01-24 |
RU2016145265A (ru) | 2018-07-19 |
BR112016029437B1 (pt) | 2022-11-29 |
CN106659727B (zh) | 2020-06-16 |
WO2015195685A1 (en) | 2015-12-23 |
ES2879331T3 (es) | 2021-11-22 |
JP6621424B2 (ja) | 2019-12-18 |
KR102419504B1 (ko) | 2022-07-12 |
CA2949545A1 (en) | 2015-12-23 |
US20150366848A1 (en) | 2015-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
MX2017005252A (es) | Metodos para la preparacion de ribosidos. | |
MX2016015695A (es) | Metodos para tratar y prevenir enfermedades de inestabilidad vascular. | |
MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
EP3203948A4 (en) | Pad, method and system for providing thermotherapy at intravascular catheter administration site | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
EP3391930A4 (en) | BALLOON CATHETER, METHOD FOR THE PRODUCTION THEREOF AND TREATMENT METHOD | |
EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
TW201613639A (en) | Methods for treating cardiovascular diseases | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
HK1258999A1 (zh) | 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物 | |
MX2017011399A (es) | Métodos para modular la densidad ósea. | |
HK1251476A1 (zh) | 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽 | |
MX2019005700A (es) | Metodos para tratar la osteocondromatosis multiple (mo). | |
UA100992U (ru) | Способ лечения гипертонически-гиперкинетической формы дискинезии желчевыводящих путей и вегетативных нарушений у больных с хроническим бескаменным холециститом | |
EP3391932A4 (en) | BALLOON CATHETER, METHOD FOR PRODUCING THE SAME, AND PROCESSING METHOD | |
UA100306U (ru) | Способ лечения гипотонической формы дискинезии желчевыводящих путей и вегетативных расстройств у больных хроническим бескаменным холециститом | |
UA104614U (uk) | Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих |